Shares of Agios Pharmaceuticals Inc. (NASDAQ:AGIO) gapped up prior to trading on Thursday . The stock had previously closed at $42.47, but opened at $42.53. Agios Pharmaceuticals shares last traded at $43.92, with a volume of 188,615 shares changing hands.

Several brokerages recently commented on AGIO. Credit Suisse Group AG reiterated a “buy” rating on shares of Agios Pharmaceuticals in a report on Tuesday, July 12th. Goldman Sachs Group Inc. reiterated a “hold” rating and issued a $46.00 target price on shares of Agios Pharmaceuticals in a report on Monday, June 13th. Janney Montgomery Scott reiterated a “neutral” rating and issued a $47.00 target price (down from $52.00) on shares of Agios Pharmaceuticals in a report on Monday, June 13th. JPMorgan Chase & Co. upgraded Agios Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $50.00 to $62.00 in a report on Monday, June 13th. Finally, Canaccord Genuity raised Agios Pharmaceuticals from a “hold” rating to a “buy” rating and increased their price target for the company from $50.00 to $90.00 in a research report on Monday, June 13th. Six equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $63.44.

The stock’s 50 day moving average price is $46.78 and its 200 day moving average price is $45.59. The firm’s market capitalization is $1.60 billion.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($0.61) EPS for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.18. The firm had revenue of $31.30 million for the quarter, compared to analysts’ expectations of $20.94 million. During the same quarter last year, the company posted ($0.13) EPS. The firm’s revenue was down 8.5% compared to the same quarter last year. Analysts forecast that Agios Pharmaceuticals Inc. will post ($3.46) earnings per share for the current year.

In other news, Director Lewis Clayton Jr. Cantley sold 627 shares of the company’s stock in a transaction dated Monday, April 25th. The stock was sold at an average price of $55.00, for a total value of $34,485.00. Following the completion of the transaction, the director now owns 128,429 shares of the company’s stock, valued at $7,063,595. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Scott Biller sold 27,500 shares of the company’s stock in a transaction dated Wednesday, June 8th. The stock was sold at an average price of $65.00, for a total value of $1,787,500.00. Following the completion of the transaction, the insider now directly owns 81,376 shares of the company’s stock, valued at approximately $5,289,440. The disclosure for this sale can be found here.

Other institutional investors have added to or reduced their stakes in the company. Mutual of America Capital Management LLC raised its position in Agios Pharmaceuticals by 0.5% in the fourth quarter. Mutual of America Capital Management LLC now owns 17,325 shares of the biopharmaceutical company’s stock worth $1,125,000 after buying an additional 86 shares during the period. State Board of Administration of Florida Retirement System raised its position in shares of Agios Pharmaceuticals by 7.7% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 22,672 shares of the biopharmaceutical company’s stock worth $1,472,000 after buying an additional 1,624 shares during the last quarter. Rhumbline Advisers raised its position in shares of Agios Pharmaceuticals by 2.5% in the fourth quarter. Rhumbline Advisers now owns 24,947 shares of the biopharmaceutical company’s stock worth $1,620,000 after buying an additional 605 shares during the last quarter. ProShare Advisors LLC raised its position in shares of Agios Pharmaceuticals by 5.9% in the fourth quarter. ProShare Advisors LLC now owns 31,258 shares of the biopharmaceutical company’s stock worth $2,029,000 after buying an additional 1,740 shares during the last quarter. Finally, GAM Holding AG raised its position in shares of Agios Pharmaceuticals by 210.9% in the fourth quarter. GAM Holding AG now owns 45,700 shares of the biopharmaceutical company’s stock worth $2,967,000 after buying an additional 31,000 shares during the last quarter.

Agios Pharmaceuticals, Inc (Agios) is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs) of metabolism using cellular metabolism as a platform. It is also engaged in the identification and validation of altered metabolic pathways within abnormal cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.